US006706728B2

(12) **United States Patent**
Hedenstrom et al.

(10) **Patent No.: US 6,706,728 B2**
(45) **Date of Patent: Mar. 16, 2004**

(54) **SYSTEMS AND METHODS FOR TREATING A MUCOSAL SURFACE**

(75) Inventors: **John C. Hedenstrom**, St. Paul, MN (US); **Michael J. Jozwiakowski**, Stillwater, MN (US); **Mark Martinez**, San Franciso, CA (US); **Kenneth R. Phares**, Chapel Hill, NC (US); **Kenneth Trofatter, Jr.**, Minnetonka, MN (US)

(73) Assignee: **3M Innovative Properties Company**, St. Paul, MN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/238,662**

(22) Filed: **Sep. 10, 2002**

(65) **Prior Publication Data**

US 2003/0045543 A1 Mar. 6, 2003

Related U.S. Application Data

(63) Continuation of application No. 09/886,012, filed on Jun. 22, 2001, now abandoned, which is a continuation-in-part of application No. 09/676,339, filed on Sep. 29, 2000, now Pat. No. 6,486,168, which is a continuation of application No. 09/479,578, filed on Jan. 7, 2000, now Pat. No. 6,245,776.

(60) Provisional application No. 60/213,420, filed on Jun. 22, 2000, and provisional application No. 60/115,253, filed on Jan. 8, 1999.

(51) **Int. Cl.**[7] **A61K 31/44**

(52) **U.S. Cl.** **514/293**; 514/292; 514/303

(58) **Field of Search** 514/293, 292, 514/303

(56) **References Cited**

U.S. PATENT DOCUMENTS

545,102	A	8/1895	Sleem
652,848	A	7/1900	Hill
1,711,341	A	4/1929	Cook
1,794,221	A	2/1931	Washburn et al.
2,518,486	A	8/1950	Mende
2,616,423	A	11/1952	Kurkjian
2,705,496	A	4/1955	Svenson

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

EP	0 894 797 A1	2/1998
JP	9-208584	8/1997
WO	93/09119	5/1993
WO	97/41884	11/1997
WO	97/48704	12/1997
WO	98/24436	6/1998
WO	99/29693	6/1999
WO	00/06577	2/2000
WO	00/09506	2/2000
WO	00/40228	7/2000
WO	00/76505	12/2000
WO	00/76518	12/2000
WO	00/76519	12/2000

OTHER PUBLICATIONS

Miller, R.L., et al., Imiquimod applied topically: a novel immune response modifier and new class of drug, international Journal of Immunopharmacology, Vol 21, 1999, pps. 1–14.

R. Snoeck, G. Andrei and E. De Clercq, "Specific Therapies for Human Papilloma Virus Infections", Current Opinion in Infectious Diseases, 1998, vol. 11, pp. 733–737.

"3M Pharmaceuticals unveils research and development and expansion plans" retrieved from STN International, No. 2138, p. 10–. . . (1996).

Harrison, C.J. et al., "Effects of Cytokines and R–837 a Cytokine Inducer on UV–Irradiation Augmented Recurrent Genital Herpes in Guinea–Pigs", Antiviral Research, 1991, vol. 15, No. 4, pp. 315–322.

Harrison C.J. et al., "Modification of Immunological Responses and Clinical Disease During Topical R–837 treatment of Genital HSV–2Infection", Antiviral Research, 1989, vol. 10, No. 4–5, pp. 209–224.

Chollet, J.L. et al., "Development of a Topically Active Imiquimod Formulation", Pharmaceutical Development and Technology, New York, NY, US Jan. 1999, vol. 4, No. 1, pp. 35–43.

Dittgen, M. et al., Acrylic Polymers. A review of Pharmaceutical Applications, STP Pharma Pratiques, Paris, FR, (1997) vol. 7, No. 6, pp. 403–437.

Wozniak, et al., The Amination of 3–nitro–1, 5–naphthyridines by Liquid Ammonia/Potassium Chemical Society, 102, pp. 511–513, Dec. 12, 1983.

Brennan, et al., "Automated Bioassay of Interferons in Micro–test Plates", Biotechniques, Jun./Jul., 78,1983.

Testerman, et al., "Cytokine Inudction by the Immunomodulators Imiquimod and S–27609", Journal of Leukocyte Biology, vol. 58, pp. 365–372, Sep. 1995.

Bachman, et al., "Synthesis of Substituted Quninolylamines. Derivatives of 4–Amino–7–Chloroquinoline", J. Org. Chem., 15 pp. 1278–1284 (1950).

Jain, et al., "Chemical and Pharmacological Investigations of Some ω–Substituted Alkylamino–3–aminopyridines", J. Med. Chem., 11 pp. 87–92 (1968).

Baranov, et al., Chem. Abs. 85, 94371, (1976).

Berenyi, et al., "Ring Transformation of Condensed Dihydro–as–triazines", J. Heterocyclic Chem., 18, pp. 1537–1540 (1981).

Buck, et al; "Successful Treatment of Vaginal Intraepithelial Neoplasia with Imiqumod 5% Cream" (unpublished manuscript being submitted for publication), no date available.

Primary Examiner—Raymond Henley, III
(74) *Attorney, Agent, or Firm*—Ted Ringsred

(57) **ABSTRACT**

A system for treating a condition associated with a mucosal surface, the system comprising an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof and an applicator device for applying the IRM compound to the mucosal surface. This system of IRM compounds and applicator may be used to treat conditions associated with mucosal surfaces such as cervical dysphasia and cervical intraepithelial neoplasia.

39 Claims, 12 Drawing Sheets